JCP is home to over five decades of generic medication production and is a cornerstone household brand for numerous products in Taiwan’s domestic market, most notably with CNS medications. The company’s chairman and CEO, PH Huang details how they have gone about utilizing their post-IPO funds to enhance the company’s commercial positioning, including the extension of their manufacturing capacities, while highlighting international expansion and diversifying into oncology as the two areas chartering JCP’s next phase of development.
As an introduction for our readers, can you please provide an overview of yourself and the company?
"My first and foremost priority is ensuring the planning and completion of our new manufacturing plant within two and half years, which will ultimately triple our production capacity."
